Beam Therapeutics (NASDAQ:BEAM) said it plans to cut approximately 20% of its workforce, or around 100 jobs, as part of a corporate restructuring initiative. As a result of the layoffs, which are ...
(Reuters) -Beam Therapeutics said on Thursday it will focus on developing its experimental sickle cell disease treatments and reduce about 20% of its current workforce, or 100 employees, as part of a ...
As you might know, Beam Therapeutics Inc. (NASDAQ:BEAM) just kicked off its latest annual results with some very strong numbers. The results were impressive, with revenues of US$378m exceeding analyst ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback